【Q】 drug tender bodies five expert database of experts really understand economics, pharmaceutical industry and medicine? Way of selection of experts is science? Set of experts selected aspects of the need?
Bidding process if the human expert evaluation factor is too large, may affect their impartiality, therefore, improve the assessment methods is growing
expert review of the bidding evaluation of medicines has a very important role and significance, but if the human factor experts, is too large, may be direct impact on the fairness of the bidding and purchasing drugs. how to improve the way medicines review, making the drugs have become more persuasive tender bidding process in the next provincial important issues must be addressed.
Recently, Jiangsu Province, tender procurement of blood products attention by the industry. In the bidding process, the relevant organization departments hope to further reduce drug prices, but the bidding company has said that prices have been down to the bottom line. The two sides deadlocked unsuccessful.
event itself will be how the trend for the time being not to discuss, but people can not help but ask: how to measure the level of product prices? this one, What is the role of evaluation experts? expert review whether there is inadequate situation? why the price is difficult to 谈拢? there is no better way to supplement or replace the expert review? this series has become the provinces in the bidding process problems to be solved.
experts too subjective? < br> In fact, since the provinces to explore their own province as the unit of procurement of medicines since the tender, the supplier has been reluctant to do on behalf of the subject have occurred in the scene, the main reason is that enterprises and experts in the bid price, difficult to reach a consensus. < br> To solve this problem, the key is to determine the price of drugs is too high or too low. but inflated the price of drugs to inhibit drug for the purpose of the tender process, the experts whether the price given is the key persuasive . journalists in the survey found that companies currently involved in the tender bidding drugs on provincial assessment results disagree.
Recently, in order to further understanding of the existing units of the provincial drug bidding and purchasing policies and the implementation of the results achieved provinces hundred valid questionnaires, 100% of the enterprises that the existing provincial drug bidding procurement process, expert review exists the phenomenon of too much subjectivity. Among them, 52.7% of enterprises believe that the but acceptable review of drugs is indeed very large, but there is no business which can be used as space.
Suggested retail price, to enter the bargaining or negotiating session until the final winning bid, or out of drugs. this process, the expert's subjective factors play an important role. In fact, the prices of some products is indeed too low, and enterprises in order to keep the market even if no price is too low profits can only accept the results, but that does not explain the drugs in the final price is reasonable. Most enterprises are considered to have reasonable, but in practice, a number of objective factors may lead to inadequate assessment of drugs. the conference, Guangdong imported products, a main person in charge of the case agent's business, told reporters.
Zhuang Huiping also share this view. She said that drug raw materials prices rose rapidly, which undoubtedly greatly increased the cost of business. But in the drug tender process, due to industry and market experts not familiar with, simply can not afford to consider whether the costs will increase business. In addition, Zhuang Huiping that drug use different raw materials, supplies, the cost and efficacy of drugs change how the inclusion of the review, the issue is worth discussing.
bidding process should be more open
reporter also found the drug in some provinces currently bidding process, although experts in the evaluation has been done to the maximum of fairness and justice, but After the bidding, there are still many enterprises on the part of the tender evaluation process there is doubt.
above a certain pharmaceutical company in Guangdong official told reporters that the generation of these questions, a large part because companies believe they can not be determined Experts suggest that the accuracy of the price. For example, the same common name of the product, why the other manufacturers of drugs bid price will be higher, which is based on what, etc., This is an important reason leading to the above controversy. professional disciplines have established the corresponding panel of experts, selected based on whether their respective areas of drugs were taken in each group of experts, extraction ratio is the number of such details, the organizers did not complete the initiative to publish the tender, while the respondents were mostly that researchers in the field, then only based on expert assessment will provide data and information given by the procurement centers, pharmaceutical experts, the mechanism, clinical efficacy, and other professional ability may be difficult to play very well, so the final form Experts suggest that price may not be enough science. In addition, all information and data experts to determine the price of drugs used in other sectors did not take the initiative to the business open, even if its price given the high price of drugs should be effective, companies will not satisfaction.
therefore, suggested that more evaluation is not yet mature
reporters in an interview that, apart from hoping to be more open and transparent assessment of drugs, the ability to intervene in the way of other tender evaluation, expert review of the potential to circumvent the possible, but also tender and business experts, the focus of attention and discussion of the content.
the Guangdong people responsible for a pharmaceutical company to make recommendations, assessment of drugs which should not to tender an expert's suggested retail price as the only criteria, relying on more objective facts and data to illustrate the real value and price of drugs to enhance the persuasiveness of pharmaceutical review.
reporter learned that the current assessment of the provincial drug tender way to explore their own way before the provinces, great changes have taken place more emphasis on the import of objective factors, such as the introduction of the average bid price of surrounding provinces, and expand the base of evaluation experts, establish and improve the pool of experts to increase the elements of the weighted average method, etc., but a relatively hot topic this year is the introduction of economic evaluation of drug possibilities and results.
related information, can Pharmacoeconomic evaluation of a number of varieties of the same types of drugs for cost and effect analysis, in order to measure the value and price of drugs. This is just the most basic economic evaluation of drugs applications can also cross the path of the deep-seated cross-species analysis between the theoretically possible for the state to develop drug list, the price mechanism, bidding and purchasing, and medical payment data provide important means of support.
However, the drug economic evaluation into the practice of bidding and purchasing medicines, companies and experts believe that the person in charge of very valuable.
Shenyang Pharmaceutical University, a pharmaceutical economist told reporters that the State has consulted the work norms sufficient data on.
Soon, the drug data and analysis platform has no sound, and therefore Chezhou the development and application of the discipline. expert review whether there is Notes>>>
just the first step toward drug bidding
experts as an important force in the evaluation, the tender evaluation of drugs play a direct role in a fair and impartial, the establishment of comprehensive databases of experts and expert classification The first step is to achieve a fair and just. but in the provinces in the bidding process, the content is still room for improvement.
First, the number of provinces and pharmaceutical database of evaluation experts have yet to be increased. current pool of experts in most provinces number of relevant documents to meet the state requirement, but a higher level of development of the pharmaceutical industry for the province, are fully capable of increasing the size and efficiency expert database, so that more experts to review the bidding and purchasing of medicines, weakening possible subjective factors, and enhance the persuasiveness of pharmaceutical review.
In addition, the province of professional experts in Expert Database classification needs to be improved. Let the professional expertise of experts to assess the drug in order to better reflect the value of pharmaceutical trial, and ultimately reflect the actual drugs The successful results.
present, many provinces in the new revised classification criteria, some places have begun to implement the new standards. there is still a small number of provinces on the expert database specialization is not enough, the drugs, equipment, supplies, etc. grouped together to clinical, economic and other content can not make accurate judgments, and thus there is objective factors expert review the case of fairness.
However, due to late start of the pharmaceutical industry, the domestic number of experts in many subject areas do less, especially some provinces in certain disciplines can not even find those who meet the requirements of evaluation experts. Therefore, in the refined classification standards, experts vacancies likely to occur or bidder information is easy to guess the situation to the expert. For this phenomenon, the general through the secondment of experts from neighboring libraries or individual professional categories ways to solve fuzzy.
Role
induced circulation change in the situation of industrial enterprises】 【Six Questions on the bid directly to the pros and cons of essential medicines have? directly bid on commercial companies the extent of impact?
manufacturer bidding directly, which means it will directly face the end; to negotiate commercial companies in a vulnerable position, forcing the manufacturers to provide better service, timely delivery, timely back section, which improve the internal management of commercial companies, to further improve the business concentration.
Recently, the national essential drug procurement and distribution Forum held in Beijing, the industry introduced to the media, a set of data: the production of essential drugs in the enterprises, 18.2% said no essential drugs in the tender. This has led to industry manufacturers directly Policy of the tender.
January 17 last year, the Ministry of Health, Office of the State Council, the rectification of the National Development and Reform Commission, State Administration for Industry, the State Food and Drug Administration, State Administration of TCM and other six ministries jointly issued a one of the highlights.
reporter then compared the Ministry of Health document issued before the 320 found that the new regulatory body for medicines made significant changes to the tender, from the centralized procurement of drugs from wholesale companies to bid directly to drug manufacturers to bid. health reform policy in the new situation is not entirely clear, the subject of the tender Role drugs exactly what will bring changes in how companies deal with issues affecting the industry and other sensitive nerve.
tender subject > If the tender by the commercial company, it means that enterprises entrusted to the commercial product the company winning the tender, the naturally only by the distribution of commercial enterprises.
administration of things, is what commercial companies, all around the tender to some extent, the main responsibility for misplaced. Reporter, bidding determines the market access of drugs belonging to the scope of product marketing, and product marketing, pharmaceutical companies should be a natural thing, therefore, drugs should tender bid by industrial enterprises as the main body and the commercial pharmaceutical distribution companies should be tender secondary entities, if the commercial companies have the resources available in the local enterprises to use, it can stand in the perspective of aid.
Yang Changshun said, progress. medicine circulation goal of treatment is to reduce the circulation, and let the manufacturers to minimize dependence on commercial companies just meet this goal. an important manifestation, but also regulate bidding and purchasing drugs is an important link. Wuhan Pharmaceutical Group Chairman Wang Xuehai blessing in an interview that the new medical reform rotating the entire pharmaceutical industry, have a certain capacity of industrial production and distribution companies will take the opportunity to expand its distribution range, or even directly to the hospital terminal distribution, and enhance hospital pharmaceutical companies to target customers ability to control. said that product sales will face new challenges of quality distributors compete for resources mm. This challenge will become more apparent in the next two years. kept too low, the operating pressure is very big business. As a result, some companies tried in the bidding lower prices, short-listed after the change in specifications, price increase in disguise, or cut corners, resulting in chaos in the tender.
this, Zhejiang Wellcome Pharmaceutical Company Ltd. Liu Zhongliang deep experience, easy to breed local protectionism. Select distribution companies to distribution. Guizhou Braun Pharmaceutical Co., Ltd. Deputy General Manager of Enterprise Group Weng innovations that: favor of the tender subject, industry concentration degree will be further improved. However, this change for the small and medium enterprises in the wholesale distribution of weak impact will be enormous. Braun, as pharmaceutical companies fully understand the national policy, but directly in the enterprises across the country to carry important documents, more trouble, and great for travel, business can not afford the light. specifications, production companies, pros and cons of how to directly participate in the bidding in the end?
Yang Changshun told reporters that, for large enterprises, are their own bidding, so the market can more easily grasp the initiative, you can swap with any commercial company to market needs, and not by others. advantages of large size of the business, brand, product advantages and the system of government affairs, professional organization of the tender are to ensure that their bid at the right price. Lee is forcing companies to face reality and enhance the professionalism of the tendering exercise and systematic, is conducive to improve the management level, to promote their long-term development. the flaw of manufacturers around the tender rules do not understand the short term, local clock resources are limited, the bidding process to control the poor, can not guarantee winning. can be successful is not quite sure, but the company has built a standardized management system and bidding process, has established a core work of the bidding system for government affairs, the sound operation of such work, will ensure a high enterprise products successful rate. Rent. is not cost-oriented. said that the sales revenue of 3 billion yuan of production enterprises, to participate more competitive centralized procurement of drugs, whether the tender from a single medication or from a variety of drug procurement cost accounting purposes, are economic. many companies bid value not only short-term economic benefits, but also to the long-term development of regional markets, as long as you can to maximize comprehensive income. agencies have the final say, drug billing cycle is too long, to the producers a great deal of financial pressure. attitude, making the response from agents manufacturing enterprises transferred to the centralized government procurement deal. small businesses in the pharmaceutical procurement, economies of scale and bargaining power are weak, drug selection is also smaller, and thus, many small and medium enterprises are facing a great problem of existence.
interview, the reporter found that in our current bidding process, the vast majority of manufacturers understanding of the bid still in its infancy, the past emphasis on marketing, neglected to do the tender of drugs, the production company to direct bid to become the key to its development.
talk about this, Wang Xuehai told reporters that the text No. 7 to the outside world has a very clear signal, that is a direct bid to encourage production companies in order to standardize the market order. we must first solve the problem of specialization. marketing strategy for the enterprise to provide reference.
fact, build a scientific evaluation system is security marked before the manufacturer directly to an important part of the tender. Analysts believe that as long as the standard before the assessment can be production companies to take direct bidding should be the way to the tender price and the right of distribution after winning in their own hands. worthy of special attention, because many small and medium business companies has long been dependent on the formation of a strong, hardly agency from the previous investment division under the changes over the tender, the tender is now even has a department of the company, its bid is still responsible for those who play the role of information, or to other agents handle all matters. This so, to require the production of enterprises are well prepared both hands. the one hand, strengthen the practice of enterprises themselves.
This initiative is the production the only way for enterprises to actively strive for. tender price, sure the right bid price, the price is too low bid rejection, long-term development for the product, the right amount of annulment is necessary. production companies to bid for more commercial companies make a weak position in negotiations, forcing the manufacturers to provide more perfect service, timely delivery, timely returns to the funds, thus contributing to improve the internal management of commercial companies, the elimination of backward business, which further enhance the commercial companies for the degree of concentration is also very good.
induced circulation change in the situation, then, in the new medical change policy is not entirely clear circumstances, the subject of drugs bid Role of drug distribution will produce what kind of impact?
Dion said innovation, the state bidding and purchasing drugs aimed at lowering production enterprises and commercial companies profits, production enterprises is bound to exacerbate the process to join the proposed national tax department of medicine production and circulation of lower tax rates, to tax the people. earned reputation. hope to encourage innovation in terms of the tender reflected. position, as the relationship between the two, depending on the resources the two sides (client resources, distribution channels, drug structure, etc.) advantage, bargaining power. If the production company's strong economic strength and scale, the tender will be directly involved in the drugs , and terminal make direct sales. If the scale commercial companies stronger, larger net sales in the region has a large monopoly advantage in the drug distribution, marketing and other aspects of the terminal net has great bargaining power, many small and medium pharmaceutical companies had commissioned a commercial bid. tenderers after the introduction of new regulations, it seems that the gradual development of this inequality is broken. industrial enterprises directly bid, and commercial companies responsible for circulation and distribution, can not be generalized.
pharmaceutical distribution chain compression is conducive to drug procurement costs down. a profound change, the current drugs have many problems in the tender will be solved gradually.
Reporter's notes>>>
tender innovation: CHAMC
we all know, reform is the original interest was a re-deployment, and make it consistent with the fundamental interests of the majority. drugs bidding system reform is also true, it is hoping to further regulate drug distribution through the order, thereby reducing drug costs, the benefit of the people, this is country-driven bidding system, a centralized drug purchasing intention and good wishes.
, however, subject to the complex environment factors, the tender of the main conversion may seem cautious. Since January 2009 six ministries on regulating the pharmaceutical procurement 7 Man industrial production enterprises, there are some urgent need for a direct bid to solve practical problems. Under the new policy of supporting health reform remains unclear circumstances, the manufacturers how to conduct scientific and reasonable standard before the assessment of the direct investment? in ; the context of bidding and purchasing, manufacturing enterprises to control the market? how to ensure that their reasonable profit margin? regions, and how a unified standard bidding? bidding process, how to reflect the terms of encouraging innovation production? in establishing a direct relationship with the hospital in , how to coordinate the procurement of the number of hospital in time to cash? commissioned agents how to bid and so on. these are still wondering whom to trade. In the context of the new medical reform, the provinces in the understanding and implementation of policies is not the same, resulting in tender mix of drugs, squeeze out competitors, but it can not be in accordance with the This allows manufacturers deviate from the track of scientific development. so, the recent disclosure of an expert, > The reasons for these problems are many, some pharmaceutical companies struggling to cope, leaving greatly increased operating costs, profit margins are not justified due consideration, because there is not uniform throughout the procurement standards, quality and price is not uniform, the operation procedures are not uniform, the breeding of local protectionism for producers fear, then there are the rules of the bidding enterprises, local contacts to build and control the bidding process so not good at, etc., but ultimately, still lies in the system design and policy landing.
I thought, However, to get manufacturer direct bid to truly become a positive, effective and feasible policies to reduce intermediate links benefit the people, but also the relief as soon as three aspects: First, improving the supporting measures. Drugs is a bidding system works and production companies to bid as much as possible to consider policy coordination with other policies, convergence. Second, the value reflects the innovation. it is necessary to re-introduction of national level guidance documents, and documents to be provided in key content is even more detailed. III Tender is to create a professional team. to adapt to the country's drug centralized procurement policy, to take corresponding measures. but their case, the production enterprises, will be implemented in all provincial government centralized drug purchasing patterns continue to explore or innovation to achieve state enterprises directly the original intention of bidding and good wishes, and then to achieve new leaps.
based drug delivery: both sides of the coin asked
】 【seven after winning companies will also face issues such as distribution and back section. everywhere in an attempt to reduce intermediate links, in some places continue to implement similar products, such as the implementation of uniform distribution model, in which the commercial temptation to self-evident, but how to solve the high distribution costs, cash allows the difficult issues such as drug distribution enterprise based at a loss right
meaning can be compared with data on a group: Although sales of essential drugs accounted for only 20% of total drug sales, drug sales share of high-end 80%, but the other indicators show the market coverage of essential medicines of 80%, while only 20% of high-end drugs. < br> In this sense, the 80% market coverage and distribution of essential drugs sufficient to evolve into a future selection of the right to battle the next few years, basic medicine system, the full impact of the implementation of the pharmaceutical business of the existing structure.
Distribution to those who have the world
The current change is the field of commercial enterprises in the future to deal with drug distribution and layout. are low-cost essential drugs Sui drugs, but for mature network, distribution capability, low operating costs of commercial companies, once the manufacturers to get distribution to obtain the distribution of qualified and commissioned, it means that companies will secure a stable source of profits. < br> In addition, the basic rights of drug distribution business on a deeper significance lies in the hospital and upstream producers end infiltration and to control. Given the current provincial tender system, the selection of distributors in the future government, manufacturing companies have chosen under the rules of distribution business and commercial voice will be greatly weakened.
Some analysts believe that, under existing circumstances, only drugs can not meet the income distribution logistics interests and needs of enterprise development, enterprises must rely on expensive drugs and other products to obtain higher profits. This requires a high-end commercial companies or hospital resources, or drugs with high-end enterprise resource. Generally speaking, if the two commercial companies in the public relations capacity, logistics capabilities, size, number of points on the strength of the similar, regardless of manufacturer or the hospitals are willing to Select companies are already cooperating distribution business.
the longer term perspective, the implementation of the basic drug system, can be said that the future pattern of China's pharmaceutical business by re-start. from Beijing and some other provinces of view, use of public medical institutions of all essential medicines and health care drugs already included in the scope of uniform distribution. With the gradual essential drug system fully implemented in many parts of the country or to explore the implementation of health insurance products, such as uniform distribution of the directory model. then, the drug distribution will not longer confined to essential medicines in the market share of 20%, of which the commercial temptation to self-evident.
After the distribution of essential drugs can do, can also be involved in drugs or other high-end Medicare hospital drug distribution. OTC market, the third terminal-based, focus on the county level hospitals and two medical institutions based marketing, while three or more appropriate time to open up the high end of the hospital market.
pharmaceutical companies the right to face the challenge of transformation. department stores; the other is the professional, characteristics of varieties of the road, or other links to the transformation of industrial chain, such as retailing.
tickets waiting to finally get back
going through a drug delivery based tickets, for many smaller commercial companies, after the jubilation that followed turned out to be more confused.
Jiangsu market, for example, the reporter learned that Jiangsu Province in the essential drug list There are 599 products Regulation In 2009 December, Jiangsu Province, to determine the eligibility of 32 distributors. ... such a person in Jiangyin
No comments:
Post a Comment